Protara Therapeutics Inc (TARA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $146.54M
Last updated: Nov 17, 2026 at 4:10 PM ET
Protara Therapeutics Inc (TARA) Statistics
Protara Therapeutics (TARA) has a market cap of $146.54M and an enterprise value of $121.39M. Its share count is up 48.68% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 17.16% below the market cap, as cash exceeds debt.
| Market Cap | $146.54M |
|---|---|
| Enterprise Value | $121.39M |
| Latest price (Nov 17, 2026) | $2.32 |
Key Dates
The next earnings report is expected on Mar 8, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 8, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 6, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 57.89% over 52 weeks and trades 18.02% below its 50-day average.
| Beta (1Y) | 1.32 |
|---|---|
| 52-Week Change | -57.89% |
| 1-Month Change | -0.43% |
| 3-Month Change | -41.41% |
| 6-Month Change | -46.54% |
| 5-Year Change | -64.16% |
| 10-Year Change | -99.37% |
| Total Return (1Y) | -57.89% |
| Total Return (3Y CAGR) | +26.35% |
| Total Return (5Y CAGR) | -19.88% |
| Return vs SPY (1Y) | -77.19% |
| Max Drawdown (1Y) | -71.83% |
| Max Drawdown (3Y) | -71.83% |
| Sharpe Ratio (1Y) | -1.50 |
| Correlation with SPY (1Y) | 0.25 |
| 50-Day Average | $2.83 |
| 200-Day Average | $4.33 |
| 52-Week Range | $2.09 to $7.82 |
| RSI (14 Days) | 42.2 |
| Average Volume (20 Days) | 839.07K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 9.01x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 9.01x |
|---|---|
| Quick Ratio | 9.01x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -55.63% over the last 12 months, against a 5-year average of -41.78%.
| Return on Equity (ROE) | -55.63% |
|---|---|
| Return on Assets (ROA) | -50.11% |
| ROE (5Y Average) | -41.78% |
| ROA (5Y Average) | -37.76% |
| ROIC (5Y Average) | -25.67% |
Scores
TARA has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$93.00K |
| Operating Income | -$85.19M |
| Pretax Income | -$78.44M |
| Net Income | -$78.44M |
| Reported EPS (TTM) | -$1.40 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 90.09% of the $156.54M in total assets.
| Cash and Equivalents | $25.15M |
|---|---|
| Total Debt | $0 |
| Net Cash | $25.15M |
| Net Cash Per Share | $0.40 |
| Working Capital | $115.28M |
| Shareholder Equity | $141.02M |
| Book Value Per Share | $2.24 |
| Total Assets | $156.54M |
| Total Liabilities | $15.52M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $1.08M of capital spending, operating cash flow left -$73.20M of free cash flow.
| Operating Cash Flow | -$72.12M |
|---|---|
| Capital Expenditures | $1.08M |
| Free Cash Flow | -$73.20M |
| FCF Per Share | -$1.24 |
| Depreciation and Amortization | $643.00K |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | -15.76% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -15.76% |
Dividends and Yields
TARA does not pay a dividend. Its free cash flow yield is -50.20%.
| FCF Yield | -50.20% |
|---|---|
| Shareholder Yield | 0.00% |
Stock Splits
The last split was a 1-for-40 reverse split on Jan 10, 2020.
| Last Split Date | Jan 10, 2020 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:40 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About TARA
What is TARA's market cap?
Protara Therapeutics has a market cap of $146.54M. Its enterprise value, which adds debt and subtracts cash, is $121.39M.
How many shares of TARA are outstanding?
Protara Therapeutics has 62.85M shares outstanding. The count is up 48.68% from a year earlier.
Does TARA pay a dividend?
No. Protara Therapeutics does not pay a dividend.
How much debt does TARA have?
Protara Therapeutics has $0 of total debt and $25.15M of cash and equivalents, a net cash position of $25.15M.
TARA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors